Last week’s hot topic on Cystic Fibrosis titled Phase 3 Trial of Inhaled Antibiotic to Treat CF-related Lung Infections Supported by $20M in New Financing was written by Daniela Semedo.
The article is focused on Savara Pharmaceuticals recently announcing that it has closed a $20 million Series C financing round, which will be used to advance a pivotal Phase 3 clinical trial of AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic being developed for the treatment of methicillin-resistant staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?